Caliper Life Sciences has been awarded US Patent No. 6,881,312, "Ultra high throughput microfluidic analytical systems and methods."
Inventors listed on the patent are Anne Kopf-Sill, Andrea Chow, Peter Jann, Morten Jensen, Michael Spaid, Colin Kennedy, and Michael Kennedy.
According to its abstract, the patent covers analytical systems and methods that use a modular interface structure for providing an interface between a sample substrate and an analytical unit, where the analytical unit typically has a particular interface arrangement for implementing various analytical and control functions. Using a number of variants for each module of the modular interface structure advantageously provides cost effective and efficient ways to perform numerous tests using a particular substrate or class of substrates with a particular analytical and control systems interface arrangement. Improved optical illumination and detection system for simultaneously analyzing reactions or conditions in multiple parallel microchannels are also provided. Increased throughput and improved emissions detection is provided by the present invention by simultaneously illuminating multiple parallel microchannels at a non-normal incidence using an excitation beam including multiple excitation frequencies, and simultaneously detecting emissions from the substances in the microchannels in a direction normal to the substrate using a detection module with multiple detectors.
Canbas has been awarded US Patent No. 6,881,575, "Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents."
Inventors listed on the patent are Masashi Suganuma and Takumi Kawabe.
According to its abstract, the patent protects compositions and methods for inhibiting Chk1 and/or Chk2 kinases. The patent also protects compositions and methods for inhibiting G2 cell arrest checkpoint, particularly in mammalian, e.g. human cells. In particular, the patent provides methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA damaging agents and treatments. Also protected are methods for screening for compounds able to interact with (e.g., inhibit) enzymes involved in the G2 cell cycle arrest checkpoint, such as Chk1 and/or Chk2/Cds1 kinase, the abstract states.
SmithKlineBeecham has been awarded US Patent No. 6,881,827, "Molecular cloning of a 7TM receptor (AXOR34) and screening methods thereof."
Inventors listed on the patent are Nabil Elshourbagy, Usman Shabon, Robert Ames, Henry Sarau, Lisa Vawter, and David Michalovich.
According to its abstract, the patent protects AXOR34 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques. Also protected are methods for utilizing AXOR34 polypeptides and polynucleotides in diagnostic assays, as well as screening assays to identify agonists and antagonists of the interaction between AXOR34 and its ligands, NmU-8, NmU-25, and NmU-23, the abstract states.
DakoCytomation has been awarded US Patent No. 6,881,580, "Environmental containment methods for a flow cytometer."
Inventors listed on the patent are Brian Hall, Kristopher Buchanan, Benjamin Kaanta, and Nathan Fox.
According to its abstract, the patent protects environmental containment methods for a flow cytometer that provides an adjustably controllable environment in which biological particles can be differentiated and droplets separated into collection containers.